5AM Venture Management LLC bought a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) in the seco

RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises t

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.81) per share which missed the analyst cons

ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both im

The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical res

This late-stage biotech innovator in rare disease therapies reported significant insider selling ami

Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor

ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors?

Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris (NASDAQ:PHVS) with a Overweight rat

The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. Whil

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE att

ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and r

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 recept

ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmac

Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.69) per share which beat the analyst consen

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE

This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a lat

All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the under

ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a lat

This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of st

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) CEO Berndt Modig sold 2,292 shares of the business's

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2

Wolfe Research analyst Andy Chen initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperform

Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the pr

Pharvaris enrolled deucrictibant XR for HAE in CHAPTER 3. Positive results could lend 30% upside to

RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and lowers

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.84) per share which missed the analyst cons

Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of brad

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights in

RBC Capital analyst Brian Abrahams initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperfor

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance

Oppenheimer analyst Justin Kim maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises t

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and r

B of A Securities analyst Tazeen Ahmad maintains Pharvaris (NASDAQ:PHVS) with a Neutral and raise

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy

Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second do